Searched query = "Parkinson disease"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
|November 15, 2019||2/4/2019||Trial of Parkinson's And Zoledronic Acid||TOPAZ: Trial of Parkinson's And Zoledronic Acid A Randomized Placebo-controlled Trial of Zoledronic Acid for the Prevention of Fractures in Patients With Parkinson's Disease||Parkinson Disease;Osteoporosis;Parkinsonism||Drug: Zoledronic Acid 5Mg/Bag 100Ml Inj;Other: Placebo||California Pacific Medical Center Research Institute||National Institute on Aging (NIA);University of California, San Francisco;Duke University;University of Pittsburgh;Parkinson's Foundation||Recruiting||60 Years||N/A||All||3500||Phase 4||United States|
|2||JPRN-UMIN000033285||2018/08/01||05/07/2018||The preventive effect of medicine for osteoporosis on osteopenia in patients with Parkinson's disease: multicenter/ non-blind/ randomised/ exploratory clinical trial||The preventive effect of medicine for osteoporosis on osteopenia in patients with Parkinson's disease: multicenter/ non-blind/ randomised/ exploratory clinical trial - The preventive effect of medicine for osteoporosis on osteopenia in patients with Parkinson's disease||Parkinson's disease||Oral bisphosphonate agent group: taking orally Minodronic Acid Hydrate (50mg) 1 tablet per 4 weeks|
Intravenous bisphosphonate agent group: injecting Zoledronic Acid (5mg) 1 ampule per 48 weeks
|Department of Orthopaedic Surgery, Niigata University Medical and Dental Hospital||Department of Neurology, Nishi-Niigata Chuo Hospital||Pending||50years-old||Not applicable||Male and Female||100||Not selected||Japan|